Teleflex Q2 Revenue Jumps 29% to $570M, Beats Estimates; Raises Adjusted EPS Outlook
TFX sits 37% above its 52-week low of $100.18.
Summary
Teleflex delivered a strong Q2 with revenue up 29% to $570.3M, beating the $559.6M consensus. Adjusted EPS from continuing operations rose to $1.76 from $1.73 a year ago. The company raised its full-year adjusted EPS guidance to $6.90-$7.20, though it cut GAAP revenue and EPS outlooks due to slower integration of the Biotronik Vascular Intervention business. The completed $1.5B OEM sale and $250M in stock buybacks strengthen the balance sheet. FDA approval for EZPLAZ and progress in the Freesolve program add pipeline momentum.
At the time of this announcement, TFX was trading at $136.78 on NYSE in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $100.18 to $144.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.